Mechanism Diagram GHK-Cu vs Growth Peptides (Key Differences) GHK-Cu - Copper binding tripeptide - Acts locally in tissue - Modulates gene expression and ECM remodelling - Not endocrine - Does not elevate GH or IGF-1 GH Secretagogues (e.g., Ipamorelin, Hexarelin, MK-677) - Act via endocrine receptors - Stimulate systemic GH release - Increase IGF-1 - Primarily hormonal These compounds operate in completely different biological domains
Unlike earlier single-target therapies, it is being studied for its ability to influence several physiological pathways at once, which may include: Glucose metabolism regulation (namely, Retatrutide lowers blood glucose levels)
However, they have also been shown to be effective for weight loss
The result is a 16-amino acid peptide that stimulates lipolysis through beta-3 adrenergic receptors on fat cells, without triggering IGF-1 elevation, insulin resistance, or the growth-promoting effects that make full HGH problematic for long-term metabolic use